Number of vacancies: 1
The Tumor Biomarkers Group led by Josep Villanueva at the Vall d´Hebron Institute of Oncology´s (VHIO) is currently offering a Laboratory Technician position. The main goal of the laboratory is to characterize the mechanisms adopted by cancer cells to communicate amongst themselves as well as with their microenvironment during tumorigenesis, and exploit these data to advance biomarker and drug target discovery.
We are seeking an organized, motivated and team-oriented individual with previous experience working in a molecular/cell biology research laboratory. The successful candidate will be part of a new initiative to identify biomarkers and characterize the mechanisms of resistance of new cancer drugs used in breast cancer therapeutics.
- Applicants must have a BSc or FPII, and at least two years of experience in molecular and cellular biology techniques.
- Experience in tumor cell culture and protein immunoassays by Western Blot and ELISA is required.
- Knowledge in fluorescence microscopy will be favourably considered.
- The candidate is expected to be able to communicate well in English.
Additional information: Salary will be based on the specific profile and experience of the candidate.
Application: Potential candidates should submit a curriculum vitae, letter of intent, and at least one reference using the form below at: email@example.com
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: http://www.vhio.net